{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia5zlgaert7t6fp5s6cxpctqp5z2hhbwsdgzjuraw5ogqxt3y3uc4",
    "uri": "at://did:plc:4mx3xqiwquszcdl2dli4v2bb/app.bsky.feed.post/3mhqamhwrly32"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihr7jbtlivk2ipsfpbpad56ytwqvc647mzwsvstntar2jbppumgyy"
    },
    "mimeType": "image/png",
    "size": 582224
  },
  "path": "/health/2026-03-23-180-000-infections-in-2024-47-000-by-2045-if-sa-rolls-out-the-twice-a-year-hiv-prevention-jab-fast-enough/",
  "publishedAt": "2026-03-23T10:17:36.000Z",
  "site": "https://mg.co.za",
  "tags": [
    "Health",
    "Antiretroviral Drugs",
    "ARVS",
    "Gilead Sciences",
    "Global Fund to Fight Malaria",
    "HIV prevention",
    "HIV Prevention Shot",
    "Hiv/aids",
    "LEN",
    "lenacapavir",
    "pre-exposure prophylaxis",
    "South African National Aids Council",
    "TB and Aids",
    "Unitaid"
  ],
  "textContent": "The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics. But how best to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what the modelling data shows",
  "title": "180 000 infections in 2024, 47 000 by 2045 — if SA rolls out the twice-a-year HIV prevention jab fast enough"
}